Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + rituximab for relapsed/refractory elderly DLBCL (phase II)
ChiCTR2100050169Phase 2Recruiting
- Sponsor
- Tianjin Union Medical Center
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Tianjin Union Medical Center. Primary endpoints: Objective response rate and Disease control rate. Started Oct 2018; status: recruiting.
02
Drugs
tucidinostatrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100050169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050169.